Beyond glycaemic control, empagliflozin reduces CV risk
in patients with T2DM
19 Jun 2019
Cardiovascular disease (CVD) is highly prevalent in patients withT2DM, accounting for over one-half of all deaths in this population.1 While T2DM-related CV complications have declined with improved care, a substantial burden of disease persists.2 On average, the life expectancy of a 60-year-old patient with T2DM is shortened by 6 years. Alarmingly, the coexistence of T2DM and CVD (ie,myocardial infarction or stroke) is associated with up to 12 years of reduced life expectancy.3 As such, in addition to the individualization of glycaemic targets, there is a need to emphasize on CV risk management for patients with T2DM.
Related MIMS Drugs